about
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-ATargeting tumor vasculature with an oncolytic virus.Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune responseMyxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.The 'supervirus'? Lessons from IL-4-expressing poxviruses.Myxoma virus in the European rabbit: interactions between the virus and its susceptible host.Novel oncolytic viruses: riding high on the next wave?Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200)Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells.Tropism of Tanapox virus infection in primary human cells.Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI.Delineation of five thyroglobulin T cell epitopes with pathogenic potential in experimental autoimmune thyroiditis.Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple modelsThe relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivoSingle dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal spore inhalation challengeEvaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein
P50
Q24672535-4B651E7C-6EE9-48BE-8576-B1CA23AD2B32Q30500348-00A6DD3E-D455-4109-BB30-01DF931345ACQ33523284-1BB5FC73-45EA-48A3-A7C8-DF787CC0EE29Q33808504-4D5695D2-1F9F-47B3-8504-3839DD6005C9Q34574890-333F3C4A-0A4B-4877-9266-9478172BB25CQ35201890-CDFD5A76-D32A-4E30-8E2C-B1555A4A79AEQ35223458-8DF97795-034D-4BD7-B3B5-D85C39767357Q35234447-33E04B49-7DED-452E-81FE-9885B8CF2950Q36014043-9DC14E39-56FE-4542-88B1-37F97E9C7A1DQ36143442-BD325538-A0D0-4C43-B4CF-3F5C55C20ADBQ36734188-FF236336-A05A-489B-B869-20002124D742Q37706734-58569D7B-B2FA-4C33-9FD4-AB383B0325D4Q39830537-52AE7267-28A7-4E70-A510-8DB8E8F108A8Q39985723-3C99856C-BA99-478F-841B-90C09B2CF896Q43222842-D4F66E4F-677C-405E-BC68-1747AADEBD7DQ45398491-C229BCD9-5E4E-4E7E-9556-2DAFE4A1FDCDQ48316344-F140C7E0-D652-4945-8E7D-F86A379D506EQ48695533-A07AF424-8703-4DD2-B33A-D4D32652C983Q52030060-C84069C8-2F3E-4AFE-8112-11072B972F84Q59323038-5577C59F-6D8F-404C-AEAC-D14D3B1DFCEBQ60571973-10042234-F82C-46D9-89EE-4A4F529DB491Q61797561-E4DE94D9-E3D4-474F-AD64-8155056BCD9BQ96341204-F2907080-93F5-4D5F-AD0C-9F8246B15FF6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marianne Stanford
@ast
Marianne Stanford
@en
Marianne Stanford
@es
Marianne Stanford
@nl
Marianne Stanford
@sl
type
label
Marianne Stanford
@ast
Marianne Stanford
@en
Marianne Stanford
@es
Marianne Stanford
@nl
Marianne Stanford
@sl
prefLabel
Marianne Stanford
@ast
Marianne Stanford
@en
Marianne Stanford
@es
Marianne Stanford
@nl
Marianne Stanford
@sl
P106
P21
P31
P496
0000-0003-0432-3707